Navigation Links
Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits

s target of p<0.05), as previously reported. This was the second primary endpoint.

Implications of these additional data

The significantly reduced sedation seen with M6G provides additional support to our view that M6G is equivalent to morphine in controlling pain but has a superior side-effect profile. This should give clinicians more confidence that patients are less likely to experience sedation with M6G. Sedation is one of the side effects of most concern associated with agents like morphine, along with respiratory depression.

The additional analysis announced today will be used to improve further the designs of the planned US Phase III clinical studies by targeting higher risk patient groups and surgical procedures where the clinical benefits from M6G will be maximised.

Neil Clark, Chief Executive of CeNeS, commented: "This further analysis of the recent Phase III trial data supports our stated goal of delivering M6G to the market as a novel analgesic for post-operative pain that has clearly defined benefits compared to morphine and other opiates. The large body of statistically significant Phase III efficacy and side effect/safety data also suggest that M6G could be uniquely positioned as an opiate analgesic for day case surgery - an additional growing market to the current focus on hospital based post-operative pain.

"It is estimated that at least 277 million units of injectable analgesics were used to treat pain in the United States in 2006. The US post-operative pain market is estimated to be $1.7 billion. CeNeS is confident that M6G will establish a strong position in the large global pain market."

For more information please contact: CeNeS Pharmaceuticals plc Neil Clark, CEO Tel: +44 (0)1223 266 466

JM Finn Geoff Nash Tel: +44(0) 207 628 9688

Financial Dynamics Ben Brewerton/Emma Thompson Tel: + 44 (0) 207 831 3113

About CeNeS Pharmaceuticals CeNeS is a biopharmaceutical company specialising i
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
3. Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration
4. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
5. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
6. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
7. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
8. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
9. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
10. Positive Statistical Analysis from Synthetic Bloods Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint
11. ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From its U.S. Phase II/III Clinical Study Of Bepotastine

Post Your Comments:
(Date:11/6/2009)..., BOTHELL, Wash., Nov. 6 ...inancial results for the three and nine months end...SCOLR Pharma,s President and CEO, said, "We contin... 12-hour ibuprofen formulation. Several potential ...ime, personnel and external resources as they eval...
(Date:11/6/2009)..., SAN DIEGO, Nov. 6 Trius Therapeu...istration statement on Form S-1 with the U.S. Secu... proposed initial public offering of shares of its...e sold in the offering will be offered by the Comp...cting as sole book-running manager, Piper Jaffray ...
(Date:11/6/2009)..., DETROIT, Nov. 6 Caraco...D ) has launched ketorolac tromethamine ophthalmic...e US Food and Drug Administration (FDA) for Sun Ph... generic Acular® ophthalmic solution on the f...h of ketorolac is therapeutically equivalent to Ac...
Breaking Medicine Technology:SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 8SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 9Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution 2LCA Applauds Senate Leadership Team Working to Secure New FDA Regulatory Authority Over Tobacco 47852 1LCA Applauds Senate Leadership Team Working to Secure New FDA Regulatory Authority Over Tobacco 47852 2U S Civil Rights Commission to Hold Public Briefing on Health Care Disparities Between Minorities and Non Minorities and Business Meeting 47848 1U S Civil Rights Commission to Hold Public Briefing on Health Care Disparities Between Minorities and Non Minorities and Business Meeting 47848 2U S Civil Rights Commission to Hold Public Briefing on Health Care Disparities Between Minorities and Non Minorities and Business Meeting 47848 3InterMune to Present at Goldman Sachs Healthcare Conference 12456 1
...BUSINESS WIRE)-May 10, 2007--Today, the,New Englan...wo,Phase III studies of Merck,s cervical cancer va... (Types 6, 11, 16, 18),Recombinant Vaccine). In th...ction against cervical, vaginal and vulvar disease...d to protect,against, HPV types 6, 11, 16, and 18....
...May 11, 2007 /PRNewswire-FirstCall/ --,NicOx S.A. ...ase 2a,study for NCX 1000, which is covered by its... preliminary analysis of 11 patients,from this pro...ed,the safety profile of NCX 1000 but did not demo...nuation of this clinical trial. As a,consequence, ...
Other Medicine Technology:New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 2New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 3New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 4New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 5New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 6New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 7New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 8New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 9New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 10New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 11New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 12New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 13New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 14New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 15New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 16New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 17New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 18New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 19New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 20New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 21New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 22New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 23New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 24New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 25New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 26New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 27New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 28New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 29New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 30New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 31New England Journal of Medicine Publishes New Data on Gardasil,Merck's Cervical Cancer Vaccine 32NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 2NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 3
(Date:11/7/2009)... October 23-25th marked the ...nd celebrities fighting the battle against pediatr...he foundation and it,s efforts for many years. , ...s) November 7, 2009 -- The weekend of October 23-2...ther anglers and celebrities fighting the battle a...
(Date:11/6/2009)...LANTA, Nov. 6 Recently a Narconon of Georgia grad...xperience with prescription drug abuse. The specia...ption drug addiction . In the report Andrew sh... more should be done to prevent prescription drug ...ing I knew I opened my eyes to my father on top of...
(Date:11/6/2009)...OTTSDALE, Ariz., Nov. 6 Healthcare Trust of Ameri... real estate investment trust, announced the execu...ent") to acquire a medical office building located...000. ,, The Hampden Place Medical Center is locat...ented, mixed-use redevelopment district. Hampden P...
(Date:11/6/2009)...KE FOREST, Ill., Nov. 6 Hospira, Inc. (NYSE: HSP...medication delivery company, today announced that ... Annual Health Care Conference on Wednesday, Dec. ...cheduled to begin at 9:30 a.m. Eastern time on Wed... interested parties through a live audiocast acces...
(Date:11/6/2009)...t-term limitations seem to wane as years go by, re...y News) -- New research suggests that people with ...ears of developing the disease are more likely to ...han others with the condition. , The findings, pub...h the disease who relapse within five years of dev...
Breaking Medicine News(10 mins):Health News:Updegraff Vision Proudly Supports The Pediatric Cancer Foundation 2Health News:Updegraff Vision Proudly Supports The Pediatric Cancer Foundation 3Health News:Narconon Drug Rehab of Georgia Graduate Featured on Local News 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 66,339 SF Medical Office Building Located in Englewood, Colorado 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 66,339 SF Medical Office Building Located in Englewood, Colorado 3Health News:Early Relapse of MS May Mean Fewer Issues Later 2
...urth Annual Physician On-Call Pay ...n, Cotter and Associates, Inc.,has published its f... and,practices, the 2008 Physician On-call Pay Sur...hysician specialty areas along,with data reported ...
...egins -, CORONA, Calif., July 25 Watson,Pharmace...harmaceutical,company, announced today that its su...Omeprazole Delayed-Release Capsules USP product in...ing the,first to file an ANDA containing a paragra...
..., Robert J. Reilly, Joins Aethon Team, PITTSBURGH...the leading developer of mobile robotics for,hospi...obert J. Reilly has,joined the company as Senior V...acy Division, brings more than 30,years of experie...
...f Companies will,showcase their unique line of can...iation of Physicists in Medicine (AAPM) annual mee... IMPAC and CMS are delivering,cutting-edge radiati...ian efficiency., "Our recent acquisition of CMS b...
...cs, Inc. today,announced that it has filed a regis...and Exchange Commission relating to the proposed i...ck. The number of shares of common,stock to be off... Securities Inc. is acting as sole book-running ma...
...ying to drop pounds, study finds , , FRIDA...ded Monday morning weigh-ins knows this unalterabl..., researchers have some science to back up dieters...es can wreak havoc on weight control, either causi...
Other Medicine News:Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2Health News:Weekends Tough on the Diet 2Health News:Weekends Tough on the Diet 3
Lacoste Sun Collection
Bvlgari Vision Collection
Aristar Eyewear Collection
...r and style. Creativity and cutting-edge design. D...ompanies, signed a new licensing agreement in Octo...985 by the famous designer duo, Domenico Dolce and...r Mediterranean roots to create the distinguishing...
Medicine Products: